Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Completed · Phase 1
Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
In brief
RATIONALE: Drugs used in chemotherapy, such as azacytidine work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth. Giving azacytidine together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when giving together with azacytidine in treating patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Key facts
- Study ID
- NCT00624936
- Run by
- Ohio State University Comprehensive Cancer Center
- People needed
- 23
- Starts
- 2008-04-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2017-08-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must be >18 with relapsed or refractory acute myeloid leukemia (AML) and high risk (by IPSS scoring) Myelodysplastic Syndromes (MDS)
- Patients with secondary AML or therapy related disease (t-AML) are eligible If decitabine or Vidaza was a prior treatment for MDS or AML patient is eligible.Prior Velcade is also permitted.
- ECOG performance status 0-2
- Life expectancy > 6 months for patients with a co-morbid medical illness
- Total bilirubin < 2.0mg/dL
- AST/ALT < 2.5 times upper limit of normal (ULN)
- Creatinine < 2.0 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception prior to and during study treatment
- Ability to understand and willingness to sign the written informed consent document
- Active infection is allowed provided it is under control
You may not qualify if…
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacytidine or bortezomib that are not easily managed
- Hypersensitivity to bortezomib, boron, or mannitol
- Uncontrolled intercurrent illness including, but not limited to:
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Serious cardiac arrhythmia
- Psychiatric illness/social situations that would limit compliance with study
- Myocardial infarction within 6 months prior to enrollment
- New York Heart Association (NYHA) Class III or IV congestive heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmia
- Electrocardiographic evidence of acute ischemia
- Active conduction system abnormalities
- ECG abnormality that is medically relevant
- Psychiatric conditions that prevent compliance with protocol or consent.
- Pre-existing neuropathy grade 2 or higher or other serious neurologic toxicity that would significantly increase risk of complications from bevacizumab therapy
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Diagnosis or treatment for another malignancy within 3 years of enrollment, with the exception of any of the following:
- Complete resected basal cell carcinoma
- Squamous cell carcinoma of the skin
- Any in situ malignancy
- Low-risk prostate cancer after curative therapy
- PRIOR CONCURRENT THERAPY:
- Prior decitabine or azacytidine for MDS or AML is allowed
- Prior bortezomib allowed
Where it is running
- Ohio State University Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.